Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Migoprotafib - Relay Therapeutics

Next Previous
Drug Profile

Migoprotafib - Relay Therapeutics

Alternative Names: GDC 1971; RG 6433; RLY-1971; RO-7517834; SHP2i

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Relay Therapeutics
  • Developer Genentech; Relay Therapeutics
  • Class Amines; Antineoplastics; Benzofurans; Naphthyridines; Piperidines; Pyrazines; Pyrazoles; Pyrazolones; Small molecules; Spiro compounds
  • Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 25 Apr 2025 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from a phase Ia/Ib trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 07 Jan 2025 Chemical structure information added.
  • 09 Oct 2024 Discontinued - Clinical-Phase-Unknown for Cancer (PO), before October 2024 (Relay Therapeutics pipeline, October 2024) (Roche pipeline, October 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top